GD-iExo-003 / Guidon Pharma - LARVOL DELTA

ExoCURE: The Effect of GD-iExo-003 in Acute Ischemic Stroke (clinicaltrials.gov) - P1/2 | N=29 | Completed | Sponsor: Xuanwu Hospital, Beijing | Recruiting ➔ Completed

Trial completion • Cardiovascular • Ischemic stroke

ExoCURE: The Effect of GD-iExo-003 in Acute Ischemic Stroke (clinicaltrials.gov) - P1/2 | N=29 | Recruiting | Sponsor: Xuanwu Hospital, Beijing | Phase classification: P1 ➔ P1/2 | Trial completion date: Aug 2025 ➔ Mar 2026 | Trial primary completion date: Aug 2025 ➔ Mar 2026

Phase classification • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo (clinicaltrials.gov) - P1 | N=29 | Not yet recruiting | Sponsor: Second Affiliated Hospital of Wannan Medical College

New P1 trial • Dermatology • Immunology • Vitiligo

ExoCURE: The Effect of GD-iExo-003 in Acute Ischemic Stroke (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Xuanwu Hospital, Beijing | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2024 ➔ May 2024

Enrollment open • Trial initiation date • Cardiovascular • Ischemic stroke • CRP • GFAP • IL10 • IL1B • IL6 • TNFA